Study ID A clearly stated aim Inclusion of consecutive patients Prospective collection of data Endpoints appropriate to the aim of the study Unbiased assessment of the study endpoint Follow-up period appropriate to the aim of the study Loss to follow up less than 5% Prospective calculation of the study size Total
Shitara 2019 2 2 2 2 0 2 2 2 14
Cutsem 2023 2 2 2 2 0 2 0 2 12
Banerji 2019 2 2 2 2 0 2 2 2 14
Peng 2021 2 2 2 2 0 2 2 2 14
Zhang2022 2 2 2 0 0 2 2 0 10
Yamaguchi 2023 2 2 2 2 0 1 2 2 13